Introduction
Methods
Patients
[18F]FDOPA production
PET imaging and analysis procedure
Statistics
Results
Group 1 (n = 22) | Group 2 (n = 9) | Group 3 (n = 18) | |
---|---|---|---|
Age (years) | 1st scan: 56 (4) | 1st scan: 54 (4) | 1st scan: 64 (3) |
2nd scan: 58 (4) | 2nd scan: 57 (4) | 2nd scan: 65 (3) | |
Sex (male, %) | 53% | 50% | 41% |
On somatostatin analogue treatment: | |||
At first scan (%) | 4.5% | 0% | 44% |
At second scan (%) | 0% | 11% | 44% |
Change of medication (%) | 4.5% | 11% | 11% (1 stopped, 1 started therapy) |
Total number of lesions evaluated | 1st scan: 0 | 1st scan: 9 | 1st scan: 56 |
2nd scan: 0 | 2nd scan: 9 | 2nd scan: 56 | |
Total number of lesions | 1st scan: 0 | 1st scan: 10 | 1st scan: 78 |
2nd scan: 0 | 2nd scan: 10 | 2nd scan: 90 | |
Interval surgery (n) | 1 (cholecystectomy) | 0 | 0 |
NET primary site (%) | GI-tract 68% | GI-tract 44% | GI-tract 65% |
Pancreas 5% | Thyroid 22% | Pancreas 6% | |
Thyroid 5% | Lung 11% | Head and neck 6% | |
Lung 5% | Adrenal 11% | Lung 12% | |
Unknown 16% | Paraganglioma 11% | Adrenal 6% | |
Ovary 6% | |||
NET grade (%) | Grade 1 84% | Grade 1 33% | Grade 1 71% |
Undefined 16% | Grade 2 22% | Grade 2 12% | |
Undefined 44% | Undefined 18% |
Group 1 (no evidence of disease) | Group 2 (1–2 lesions) | Group 3 (3–10 lesions) | |
---|---|---|---|
Activity administered (MBq) | [18F]FDOPA-L: 192 (2.3) | [18F]FDOPA-L: 205 (3.3) | [18F]FDOPA-L: 180 (7.9) |
[18F]FDOPA-H: 204 (4.0) | [18F]FDOPA-H: 192 (11.2) | [18F]FDOPA-H: 205 (2.1) | |
p value (t test) | 0.05 | 0.10 | < 0.001* |
Injected mass (µg) | [18F]FDOPA-L: 5204 (356) | [18F]FDOPA-L: 4614 (1028) | [18F]FDOPA-L: 5167 (694) |
[18F]FDOPA-H: 515 (50) | [18F]FDOPA-H: 1205 (371) | [18F]FDOPA-H: 885 (283) | |
p value (t test) | < 0.001* | 0.005* | < 0.001* |
Background region | SUVmean [18]FFDOPA-L | SUVmean [18]FFDOPA-H | p value | Effect size r |
---|---|---|---|---|
Striatum | 1.21 (1.11–1.36) | 1.36 (1.09–1.49) | 0.011 | − 0.36a |
Heart | 1.52 (1.25–1.77) | 1.62 (1.39–1.85) | 0.006 | − 0.39a |
Aorta | 1.12 (1.04–1.22) | 1.18 (1.05–1.31) | 0.004 | − 0.40a |
Liver | 1.64 (1.45–1.74) | 1.67 (1.48–1.86) | 0.068 | − 0.26a |
Gallbladder | 2.65 (1–50-4.31) | 2.90(0.96–4.17) | 0.540 | − 0.09b |
Pancreas (head) | 1.66 (1.39–1.94) | 1.59 (1.34–1.89) | 0.255 | − 0.17b |
Pancreas (body) | 1.47 (1.19–1.75) | 1.53 (1.32–1.87) | 0.174 | − 0.20a |
Pancreas (tail) | 1.46 (1.22–1.73) | 1.55 (1.34–1.84) | 0.010 | − 0.38a |
Left kidney | 2.73 (2.36–3.04) | 2.83 (2.55–3.39) | 0.028 | − 0.31a |
Right kidney | 2.74 (2.45–3.02) | 2.99 (2.70–3.67) | 0.000* | − 0.59a |
Left adrenal gland | 2.12 (1.86–2.72) | 2.50 (1.98–3.26) | 0.000* | − 0.52a |
Right adrenal gland | 2.34 (1.83–3.05) | 2.49 (2.15–3.30) | 0.005 | − 0.41a |
Group | SUVmax FDOPA-L | SUVmax FDOPA-H | p value | Effect size r |
---|---|---|---|---|
II (n = 9) | 5.53 [4.29–8.62] | 7.02 [3.14–10.79] | 0.67 | − 0.13a |
III (n = 56) | 5.19 [3.56–10.00] | 6.83 [4.30–14.64] | < 0.001* | − 0.58a |